The Latest Breaking News from Nasdaq

Rivian Automotive Inc (NASDAQ:RIVN) plans to establish a large-scale wind turbine at its Normal manufacturing campus in Illinois. The automaker expects to generate clean energy to enable new R1 vehicles to be powered by renewables for their first charge. Rivian installed a 783-kilowatt solar canopy in early 2022, which is scheduled to begin…

Electric car maker Lucid Group Inc (NASDAQ:LCID) has opened its first studio location in Denver, Colorado, at the Cherry Creek Shopping Center. The studio marks twenty-seven studios and service center locations open in North America. The Lucid Studio in Cherry Creek will be open to the public on June 18. "The state of…

BMO Capital has initiated coverage on Centessa Pharmaceuticals plc (NASDAQ:CNTA) with a price target of $19 (293% upside), and an Outperform rating. The analyst writes that ZF874 is a differentiated oral therapy as it addresses the root cause of AATD. Early ZF874 data (N=2) demonstrated therapeutic efficacy in patients, but liver toxicity was also flagged.…

BMO Capital initiated coverage of Intellia Therapeutics Inc (NASDAQ:NTLA) with a Market Perform rating and a $54 target price.  The analyst says Intellia's gene-editing platform could potentially deliver transformative therapies.  But challenges around the lack of clarity around an IND approval in the U.S., ongoing CRISPR/Cas9 IP litigations with Editas Medicine Inc (NASDAQ:EDIT), and high patient…

BMO Capital initiated coverage on Beam Therapeutics Inc (NASDAQ:BEAM) with a Market Perform rating and a price target of 41. BMO writes that it appreciates the high potential of Beam's next-generation editing approach, but clinical validation is yet to be established. Preclinical base editing data point to a favorable benefit/risk profile. Also Read: Pfizer, Beam…

BMO Capital Markets initiated coverage on Graphite Bio Inc (NASDAQ:GRPH), with a price target of $12 and an Outperform rating. The analyst notes that Graphite's gene editing approach involves a DNA repair mechanism that is known to be less vulnerable to errors.  BMO writes that Graphite's platform is expected to be safer than existing…

BMO Capital Markets initiated coverage on Legend Biotech Corporation (NASDAQ:LEGN) with a price target of $77, and an Outperform rating. The analyst says the company's recently approved Carvykti for multiple myeloma is best-in-class late-line CAR T therapy. Related: EMA's CHMP Clears Janssen, Legend's Multiple Myeloma CAR-T Therapy Though the analyst expects a gradual increase in sales due…

This whale alert can help traders discover the next big trading opportunities. Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity scanner.

Vertex Pharmaceuticals (NASDAQ:VRTX) has outperformed the market over the past 20 years by 8.19% on an annualized basis producing an average annual return of 15.06%. Currently, Vertex Pharmaceuticals has a market capitalization of $67.67 billion.

Verisk Analytics (NASDAQ:VRSK) has outperformed the market over the past 10 years by 2.09% on an annualized basis producing an average annual return of 12.86%. Currently, Verisk Analytics has a market capitalization of $25.64 billion.

Tesla Inc (NASDAQ: TSLA) was trading about 2% higher on Friday, rebounding slightly from a bearish day on Thursday, which saw the stock slide about 4% in tandem with the general markets.